An observational study in Midline Catheter, Lidocaine Infusion and Chronic Pain, sponsored by Medical University of Warsaw. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Medical University of Warsaw · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Chronic Pain with a site in Poland — 5 open to participants now, 5 under way, none of them phase 3. Chronic Pain · Poland.
Among the 21 studies in Chronic Pain with a site in Poland, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 19th registered.
3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.
Browse Chronic Pain studies →5 of the 21 studies in Chronic Pain with a site in Poland are open now. Recruiting first, the newest first:
4th Military Clinical Hospital with Polyclinic, Poland · Sites in Poland
Ages 18+
4th Military Clinical Hospital with Polyclinic, Poland · Sites in Poland
Ages 18–90
Pawel Sokal · Sites in Poland
Ages 18–80
Medical University of Warsaw · Sites in Poland
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 120 across 753 observational studies indexed under Chronic Pain.
Median enrollment 79 across the 16 interventional studies, 202 across the 5 observational. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 21 have an industry lead sponsor. The 10 most frequent:
Medical University of Warsaw is the lead sponsor of 326 studies on the registry; 87 are open to participants now.
Medical University of Warsaw has 3 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Chronic Pain with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy, safety and practicality of using midline catheters for repeated intravenous lidocaine infusions in an outpatient pain management setting. Adult patients requiring serial lidocaine infusions for chronic pain will be enrolled and receive treatment through midline catheters over ten sessions.
The study will investigate if the midline catheters are a safe and effective option for delivering repeated lidocaine infusions in the outpatient setting, offering a balance between ease of placement, acceptable complication risk and good patients' comfort.
Our study population is patients qualified for daily lidocaine infusion therapy for chronic pain. Patients are planned to receive an infusion daily for 10 days with 2 days weekend pause. The total therapy time is planned for 12 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who receive a midline catheter for lidocaine infusion daily for ten days with two days weekend pause.
Successful lidocaine infusion therapy without the need for additional venous access
Percentage of patients who received a daily lidocaine infusion for 10 days with a 2-day pause in an outpatient setting who did not require additional venous access.
Time frame: 12 days (from midline insertion to the end of the therapy)
Midline Catheter Maintenance Duration
The total duration (in days) that each patient maintains a functional midline catheter without premature removal.
Time frame: 12 days (from midline insertion to the end of the therapy)
Number of Participants with Premature Catheter Removal and Reasons
The primary reason for premature catheter removal will be documented, including: occlusion, inadvertent removal, extravasation, suspected infection, confirmed infection, thrombosis, catheter malfunction, phlebitis, or removal at the patient's request.
Time frame: 12 days (from midline insertion to the end of the therapy)
A-DIVA scale score
A scale used for the assessment of predicted difficulties in securing difficult intravenous access.
Time frame: The onset of therapy
Patient's satisfaction score
Patient satisfaction scores measured on a 0-10 scale
Time frame: 12 days (from midline insertion to the end of the therapy)
Number of catheter leakage events
Catheter leakage events is defined as leakage of blood or fluids from the puncture site.
Time frame: 12 days (from midline insertion to the end of the therapy)
Number of patients with phlebitis
Phlebitis is defined as infiltration/swelling or pain around the insertion site with medication or fluid administration
Time frame: 12 days (from midline insertion to the end of the therapy)
Total number of upper extremity deep venous thrombosis events
This is defined as symptomatic or asymptomatic DVT, verified by ultrasound or computed tomography. The total number of upper extremity DVT events will be recorded by study arm.
Time frame: 12 days (from midline insertion to the end of the therapy)
Number of patients who requested catheter removal
The number of patients who requested catheter removal due to discomfort or other reasons.
Time frame: 12 days (from midline insertion to the end of the therapy)
Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.
Of 336 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 56. This study's planned 20 months is below that.
Counting every sponsor, half of 362 studies reached it within 24 months; a quarter within 12 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Warsaw →